Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
Status:
Completed
Trial end date:
2021-06-02
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled trial wherein subjects with breast cancer will be
randomized to receive either 20 mg oral melatonin or placebo the night before their first RT,
nightly throughout their RT, and for an additional 2 weeks following the completion of their
RT. After informed consent is obtained from eligible subjects, they will then be
electronically randomized on a 1:1 ratio to melatonin treatment or placebo. The subjects will
be stratified according to treatment duration (less than 3 weeks; equal to or greater than 3
weeks) and prior chemotherapy.